Anlon Healthcare Limited, established in 2013, is a chemical manufacturing company specializing in the production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), specialty chemicals, and fine chemicals. The company focuses on high-quality products for the pharmaceutical industry, catering to both domestic and international markets. With a strong emphasis on research and development, Anlon Healthcare has positioned itself as a key player in the pharma intermediates sector, benefiting from the growing demand in India’s pharmaceutical ecosystem.
IPO Details
The Anlon Healthcare IPO is a mainboard public issue set to raise ₹121.03 crore through a fresh issue of 1.33 crore equity shares. There is no offer-for-sale component in this IPO. The price band has been fixed at ₹86 to ₹91 per share. The minimum lot size is 164 shares, requiring a minimum investment of approximately ₹14,104 for retail investors at the lower end of the price band, and up to ₹14,924 at the upper end.
- Subscription Dates: The IPO opens for subscription on August 26, 2025, and closes on August 29, 2025.
- Allotment and Listing: The basis of allotment is expected to be finalized on September 1, 2025, with shares tentatively listing on the BSE and NSE on September 3, 2025.
- Book Running Lead Manager: Interactive Financial Services Ltd.
- Registrar: Kfin Technologies Ltd.
The IPO is part of a wave of upcoming public issues, including others like Vikran Engineering IPO, highlighting activity in the Indian capital markets.
Financial Performance
Anlon Healthcare has demonstrated robust growth in recent years. For the fiscal year ended March 31, 2025, compared to March 31, 2024, the company’s revenue surged by 81%, while profit after tax (PAT) jumped by 112%. This strong financial trajectory underscores the company’s operational efficiency and market demand for its products. Investors should review the Red Herring Prospectus (RHP) for detailed financial statements and ratios.
Objects of the Issue
The net proceeds from the IPO will be utilized for the following purposes:
- Funding capital expenditure for the proposed expansion of manufacturing facilities.
- Repayment or prepayment of certain outstanding secured borrowings (term loans).
- Meeting incremental working capital requirements.
- General corporate purposes.
These allocations aim to enhance production capacity, reduce debt, and support ongoing operations, positioning the company for sustained growth in the competitive pharmaceutical chemicals market.
Grey Market Premium (GMP) and Market Sentiment
As of recent reports, the grey market premium (GMP) for Anlon Healthcare shares is around ₹20-25 per share, indicating potential listing gains of approximately 22-27% over the upper price band. However, GMP is unofficial and can fluctuate based on market conditions. Analysts suggest subscribing if aligned with long-term investment goals, given the company’s growth in the pharma sector, but caution about market volatility.
Risks and Considerations
Investing in the Anlon Healthcare IPO comes with inherent risks, as outlined in the RHP:
- Quality and Compliance Risks: The company must adhere to stringent technical specifications, quality standards, and regular audits by customers. Non-compliance could result in loss of business, order cancellations, warranty claims, and adverse impacts on operations and finances.
- Industry Risks: Exposure to fluctuations in raw material prices, regulatory changes in the pharmaceutical industry, and competition from larger players.
- Market Risks: General economic conditions, interest rate changes, and stock market volatility could affect listing performance.
Potential investors are advised to consult the RHP for a full list of risk factors and conduct thorough due diligence.
Should You Subscribe?
Anlon Healthcare’s IPO presents an opportunity for investors interested in the pharmaceutical and chemical manufacturing space, backed by strong financial growth and expansion plans. With India’s pharma industry projected to grow significantly, the company could benefit from this trend. However, subscription decisions should factor in personal risk tolerance, market conditions, and professional advice. For more details, refer to the official RHP.
